We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Alzheimer's Linked to Rare Gene Mutation

By LabMedica International staff writers
Posted on 29 Nov 2012
A link has been established between Alzheimer's disease (AD) and a rare gene mutation that affects the immune system's inflammation response.

The discovery supports an emerging theory about the role of the immune system in the development of AD as a rare mutation in a gene called triggering receptor expressed on myeloid cells 2 (TREM2) that helps activate immune system responses, and raises the risk for developing the disease. More...


A study led by scientists at University College London (UK) used data on a total of 25,000 people. After homing in on the TREM2 gene using new sequencing techniques, they carried out further sequencing that identified a set of rare mutations that occurred more often in 1,092 Alzheimer's disease patients than in a group of 1,107 healthy controls. With further follow-up studies involving a large number of Alzheimer's disease patients and controls, they evaluated the most common mutation known as R47H, and confirmed that this variant of TREM2 substantially increases the risk for Alzheimer's disease.

In a separate study, a team led by deCODE Genetics (Reykjavik, Iceland) involved collaborators from Iceland, Holland, Germany, and the USA. It too found a strong link between the R47H variant and AD, and, in addition, discovered the variant also predicts poorer cognitive function in older people without Alzheimer's. The company's genome sequencing and genotyping technology identified approximately 41 million markers, including 191,777 functional variants, from 2,261 Icelandic samples.

Kari Stefansson, MD, PhD, CEO and cofounder of deCODE Genetics, said "The discovery of variant TREM2 is important because it confers high risk for Alzheimer's and because the gene's normal biological function has been shown to reduce immune response that may contribute to the disease." Both studies were published on November 14, 2012, in the New England Journal of Medicine (NEJM).

Related Links:

University College London
deCODE Genetics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Automated Immunoassay Analyzer
SuperFlex™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.